WO2005094867A1 - ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 - Google Patents
ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 Download PDFInfo
- Publication number
- WO2005094867A1 WO2005094867A1 PCT/JP2005/006398 JP2005006398W WO2005094867A1 WO 2005094867 A1 WO2005094867 A1 WO 2005094867A1 JP 2005006398 W JP2005006398 W JP 2005006398W WO 2005094867 A1 WO2005094867 A1 WO 2005094867A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- gene
- interleukin
- herpes simplex
- simplex virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- the present invention relates to an anti-cancer effect enhancer for viral therapy comprising interleukin as an active ingredient.
- the present invention also relates to a method for preventing or treating cancer, which comprises administering a recombinant herpes simplex virus and interleukin in combination.
- the viral genome has been genetically engineered based on knowledge such as the molecular and cellular mechanisms of viral infection and the genetic mechanism of cancer development and the molecular and biological mechanisms of cancer cell growth. Attempts have been made to create viruses that selectively replicate in cancer cells and apply them to cancer treatment.
- Cancer treatment viruses that have been modified by gene recombination to selectively replicate only in cancer cells replicate in situ when infecting cancer cells, killing the host cancer cells in the process. The replicated virus is scattered around and infects cancer cells again, and then repeats replication ⁇ cell death ⁇ infection to exert an antitumor effect.
- therapeutic viruses that are infected with normal cells do not replicate, so normal tissue is not harmed.
- a mutant virus for example, a mutant virus in which the thymidine kinase (tk) gene is deleted from the genome of a simple herpesvirus type I (hereinafter referred to as “HSV-1”) (hereinafter referred to as “dlsptk”). "). Although dlsptk cannot synthesize viral DNA in normal cells and cannot replicate, tumor cells that are proliferating have high tk activity, so that the missing virus tk is compensated and the virus can replicate. Sensation of this dlsptk to tumor cells It has been shown in animal brain tumor models that, when stained, it specifically destroys only tumor cells and exerts a therapeutic effect (see, for example, Non-Patent Document 1).
- HSV-1 is classified as an enveloped double-stranded DNA virus, and has the following characteristics that are useful for cancer treatment. 1) Infects all types of human cells; 2) Virus life cycle and genome sequence are elucidated; 3) Most of the viral genes are known to function and add genetic manipulation 4) Because the viral genome is large (about 152 kb), large genes or multiple genes can be integrated. In addition, HSV-1 has the following advantages suitable for clinical application: 5) Relatively low!
- ⁇ Multiplicity of infection can kill all cells; 6) Antiviral that suppresses proliferation 7) Blood anti-HSV-1 antibody does not affect the spread of viral cell infection; 8) Due to the presence of mice and monkeys that are sensitive to HSV-1, 9) Pre-clinical assessment of safety and efficacy is possible; 9) Viral DNA is not incorporated into the host cell genome and is extrachromosomal.
- HSV-1 (hereinafter referred to as "G207") in which the y34.5 gene has been deleted and the ICP6 gene has been inactivated as a cancer therapeutic virus. HSV that played an important role (see, for example, non-patent documents 2 to 14), and in addition to the above two genes, the IC P47 gene (also a 47 gene) was inactivated. 1 (hereinafter referred to as “G47 ⁇ ”; see, for example, Patent Document 1 and Non-Patent Document 15). G207 and G47A have lost the ability to replicate in normal tissues, but retain the ability to replicate in tumor cells. In particular, G47A is highly useful as a therapeutic virus because of its high tumor specificity and safety by mutating three genes.
- mice with a normal immune system have conducted research using mice with a normal immune system. It was clarified that specific antitumor immunity was raised and its antitumor effect was enhanced (see, for example, Non-Patent Documents 6, 7 and 16).
- N18 tumor neuroroblastoma
- CTL systemic anti-T-lymphocytes
- CTL cytotoxic T lymphocytes
- Tumor immunity was induced and growth of distant subcutaneous or intracerebral tumors was also suppressed.
- Cure with G207 treatment The mice acquired tumor-specific protective immunity, and N18 cell-specific CTL activity was maintained for over 1 year.
- intratumoral administration of HSV-1 for cancer treatment also acts as an in situ cancer vaccine, does not require identification of tumor antigens, and is simpler than ex vivo methods that require culturing of tumor cells and the like.
- treatment of the primary lesion is clinically advantageous because it may also be able to control metastatic lesions via systemic antitumor immunity.
- Patent Document 1 US2002Z0187163A1 Publication
- Non-Patent Document 2 Chahlavi, A. et al .; Neoplasia 1: 162-169 (1999)
- Non-Patent Document 3 Hunter, W. D. et al .; J Virol 73: 6319-6326 (1999)
- Non-Patent Document 4 Chahlavi, A. et al .; Gene Ther 6: 1751-1758 (1999)
- Non-Patent Document 5 Nakamura, S. et al .; Glia 28: 53-65 (1999)
- Non-Patent Document 6 Todo, T. et al ,; Hum Gene Ther 10: 2741-2755 (1999)
- Non-Patent Document 7 Todo, T. et al ,; Hum Gene Ther 10: 2869-2878 (1999)
- Non-Patent Document 8 Todo, T. et al ,; Cancer Gene Ther. 7: 939-946 (2000)
- Non-Patent Document 9 Markert, JM. Et al ,; Gene Ther. 7: 867-874 (2000)
- Non-Patent Document 10 Todo, T. et al ,; Mol. Ther. 2: 588-595 (2000)
- Non-patent literature ll Nakano, K. et al ,; Mol. Ther. 3: 431-437 (2001)
- Non-patent document 12 Varghese, S. et al ,; Hum. Gene Ther. 12: 999-1010 (2001)
- Non-patent document 13 Jorgensen, TJ. Et al ,; Neoplasia 3: 451-456 (2001)
- Non-Patent Document 14 Todo, T. et al ,; San Diego, Academic Press: 45-75 (2001)
- Non-Patent Document 15 Todo, T. et al ,; Proc. Natl. Acad. Sci. USA 98: 6396 -6401 (2001)
- Non-Patent Document 16 Toda M. et al ,; Hum. Gene Ther., 10: 385-393 (1999)
- recombinant HSV herpesviruses such as G207
- G207 recombinant HSV
- a sufficient amount of virus can be delivered into the tumor tissue. This is one of the conditions to exert the effect.
- recombinant HSV recombinant herpesviruses
- viral therapy will be more useful.
- the antitumor immunity effect can be enhanced among the anticancer effects of virus therapy, the anticancer effect can be exerted on parts other than the cancer tissue to which the virus has been administered, and higher treatment can be achieved even in metastatic lesions. It is thought that an effect can be obtained.
- an object of the present invention is to provide a medicine that effectively and safely enhances the anticancer action of virus therapy, particularly the antitumor immunity action, and a method for preventing or treating cancer using this medicine.
- interleukin 18 when administering recombinant HSV that is selectively amplified in cancer cells for cancer treatment, interleukin 18 (hereinafter referred to as “interleukin 18”) It was found that the therapeutic effect can be enhanced by co-administering “IL-18”, and that this effect can be sufficiently obtained even at sites other than the cancer tissue to which HSV was administered. In addition, when interleukin 18 was administered systemically, the effect was further enhanced by administering or expressing interleukin 12 locally in the tumor, and the present invention was completed.
- An anti-cancer effect enhancer for viral therapy comprising interleukin as an active ingredient, characterized by being administered systemically in combination with a recombinant herpes simplex virus that selectively replicates cancer cells;
- a method for preventing or treating cancer comprising administering in combination a recombinant herpes simplex virus that selectively replicates cancer cells and interleukin;
- a therapeutic or preventive agent for cancer including recombinant herpes simplex virus that replicates selectively in cancer cells, characterized by being injected into tumor tissue in combination with systemic administration of interleukin-18
- the recombinant herpes simplex virus is a gene in which the ⁇ 34.5 gene and the ICP6 gene are deleted or inactivated, and the genomic DNA encodes interpokin 12 A therapeutic or prophylactic agent for cancer, which is inserted in a configuration in which can be expressed;
- the recombinant herpes simplex virus further relates to the cancer therapeutic or prophylactic agent according to [15] above, wherein the ICP47 gene is further deleted or inactivated.
- a sufficiently low amount of non-toxic interleukin is used in combination with a recombinant herpes simplex virus that selectively replicates cancer cells.
- a recombinant herpes simplex virus that selectively replicates cancer cells.
- the effect of viral therapy can be remarkably enhanced.
- IL-18 is administered systemically, the effect can be further enhanced by administering IL-12 locally to the tumor.
- the combined administration of these interleukins enhances the anti-tumor immunity, particularly by viral therapy, and improves the therapeutic effect at sites other than the tumor tissue to which the virus has been administered. This suggests that the method according to the present invention is effective for metastases occurring in a plurality of places, and makes virus therapy more useful.
- viral therapy means that it is selectively replicated in cancer cells by genetic engineering modification, or due to natural mutation or the original nature, and cannot be replicated in normal cells! It means a therapy that cures cancer by destroying only cancer cells by administering virus.
- viruses used in virus therapy include, for example, recombinant HSV modified to selectively replicate cancer cells, and natural mutation that replicates selectively to cancer cells.
- Svirus examples include HSV in which the ⁇ 34.5 gene and the ICP6 gene have been deleted or inactivated, and further, HSV in which the ICP47 gene has been deleted or inactivated.
- the y 34.5 gene product is a protein that antagonizes the function of double-stranded RNA-activated protein kinase (PKR).
- PPKR RNA-activated protein kinase
- HSV-1 infection phosphorylated in response to HSV-1 infection, which phosphorylates the translation initiation factor elF-2 ⁇ , thereby inhibiting viral protein synthesis. Therefore, if the ⁇ 34.5 gene does not function, virus replication is suppressed in normal cells.
- PKR is already suppressed in cancer cells, especially those in which the Ras signaling pathway is active, so that the virus can be replicated even with the mutant HSV-1 lacking ⁇ 34.5.
- the ICP6 gene is a gene encoding a large subunit of ribonucleotide reductase (RR).
- RR ribonucleotide reductase
- HSV from which the ⁇ 34.5 gene and the ICP6 gene have been deleted or inactivated includes, for example, the above-mentioned G207.
- Three of the ⁇ 34.5, ICP6, and ICP47 genes are deleted.
- An example of the inactivated HSV is G47 A described above.
- G47 ⁇ is suitable for viral therapy because of its triple tumor mutation and high replication tumor specificity and safety.
- the anti-cancer effect enhancer for viral therapy according to the present invention contains interleukin as an active ingredient.
- Interleukin is a general term for proteinaceous biologically active substances produced by immunocompetent cells such as lymphocytes, monocytes, and macrophages. To date, 29 types of IL-1 to IL-29 have been known.
- the interleukin contained in the anticancer activity-enhancing agent according to the present invention is not particularly limited as long as it enhances its anticancer activity when used in combination with viral therapy, but it is IL-12, which is a natural killer cell stimulating factor.
- IL-18 which is cloned as a site-power-in produced by Kupffer cells, has the same p40 subunit as IL-18, and was discovered as a factor that strongly induces the proliferation of memory T lymphocytes.
- IL-18 is an inflammatory site force-in with a molecular weight of 18,000 known as Interferon ⁇ inducing factor (IGIF).
- Interferon ⁇ (hereinafter “ It is known to have biological activities such as induction of production, enhancement of sputum cell activity, enhancement of expression of Fas ligand in lymphocytes, and induction of granulocyte macrophage 'colony-stimulating factor production. RU
- Interleukin alone has been reported to show anticancer activity, but it has sufficient effects Therefore, it must be administered at a high concentration, and its practicality is low from the viewpoint of side effects and the like.
- the virus when used in combination with recombinant HSV as an anti-cancer activity enhancer according to the present invention, the virus is administered alone by administering an interleukin at a sufficiently low concentration that does not exhibit toxicity. A significantly higher anticancer effect can be obtained than when it is used.
- IL-18 greatly improved the anticancer effect even at a site different from the tumor tissue to which the virus was administered. This indicates that IL-18 contributed to the enhancement of anti-tumor immunity among the anti-cancer effects of virus therapy, and the anti-cancer effect enhancer according to the present invention was used in cancers occurring in multiple locations. It is also useful for cancer patients with metastases.
- the above-described effects of systemic administration of IL-18 are further enhanced by locally administering IL-12 around the tumor tissue.
- IL-18 and IL-12 are administered systemically, they exhibit anti-cancer effects but often have strong side effects.
- the local administration of IL-12 provides an effect of enhancing the anticancer effect by the combined use of recombinant HSV and IL 18, and can suppress the occurrence of side effects. It is.
- the method for local administration of IL-12 is not particularly limited.
- the gene encoding IL-12 is inserted in the genomic DNA of the recombinant HSV used in the present invention so that the gene can be expressed, and the recombinant HSV is administered.
- the recombinant HSV may be administered only around the tumor tissue by injection administration, or may be administered systemically by intravenous administration or the like. This is because the recombinant HSV according to the present invention grows selectively in cancer cells, so that IL12 is expressed only in tumor cells even when administered systemically.
- IL-12 protein when IL-12 protein is directly administered separately from recombinant HSV, it may be administered locally by injection or the like around the tumor tissue.
- a gene encoding IL-12 is inserted into the recombinant HSV genomic DNA in such a way that it can be expressed.
- the gene is functionally linked to the downstream of the promoter in the HSV genomic DNA. Means that it has been inserted. “Functionally bound” means that the ⁇ 12 gene is linked to the promoter so that transcription of the IL 12 gene located downstream of the transcription factor starts binding to the promoter. Means that. Use the promoter originally present in HSV genomic DNA Alternatively, it can be inserted into the HSV genomic DNA as an expression cassette along with the IL-12 gene.
- the interleukin contained in the anticancer activity enhancer according to the present invention may be derived from a living body or may be produced by a genetic engineering technique. When used for human treatment, human interleukins are most preferred.
- the dosage form of the anticancer activity enhancer according to the present invention is not particularly limited, and may be oral or parenteral.
- mammals e.g., humans, mice, rats, guinea pigs, rabbits, dogs, horses, monkeys, etc.
- the dosage is determined according to the severity of symptoms, age, sex, weight, and susceptibility of the patient.
- Administration method, administration time, administration interval, nature of pharmaceutical preparation, preparation, type, type of active ingredient, etc. and not particularly limited, but the amount of interleukin contained as an active ingredient is about 5g, preferably about 5g About 20 mg / zg! About 500 mg, more preferably about 100 g to about 25 mg, and about 0.03 to SOOO / z gZkg for injection, preferably 0.1 to 1000 g /
- Each dose can be divided into 1 or several doses in the kg range.
- the anticancer activity enhancer that is effective in the present invention can be formulated by a conventional method by mixing interleukin with a pharmaceutically acceptable carrier known per se.
- the dosage form is not particularly limited, and tablets, powders, fine granules, granules, coated tablets, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, Forces including nasal drops, ear drops, nops, lotions and the like Particularly preferred are injections.
- excipients for formulation, commonly used excipients, binders, disintegrants, lubricants, colorants, flavoring agents, and if necessary, stabilizers, emulsifiers, absorption enhancers, surfactants, pH adjusters, Preservatives, anti-oxidants and the like can be used, and it can be formulated by conventional methods by combining components generally used as raw materials for pharmaceutical preparations.
- animal and vegetable oils such as soybean oil, beef tallow and synthetic glycerides; hydrocarbons such as liquid paraffin, squalene and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; Alcohol and other higher alcohols; silicone oil; silicone oil; polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester , Surfactants such as polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene block copolymer; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, methylcellulose Lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol, and sorb
- Inorganic powder purified water and the like.
- Excipients include, for example, lactose, corn starch, sucrose, glucose, mannitol, sorbitol, crystalline cellulose, dicarboxylic acid, etc .
- binders include, for example, polybulal alcohol, polybull ether, methylcellulose, Ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl pyrrolidone, polypropylene glycol 'polyoxyethylene' block polymer, medalmine, calcium citrate, dextrin, pectin, etc .
- disintegration Examples of the agent include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, calcium oxalate, dextrin, pectin, carboxymethyl cellulose and calcium;
- the lubricant include magnesium stearate, talc, polyethylene glyco
- antioxidant, ascorbic acid, a tocopherol, etc. are permitted to be added to pharmaceutical products Each one is used.
- the oral preparation is prepared by adding excipients, further binders, disintegrants, lubricants, coloring agents, flavoring agents, and the like as necessary, and then adding powders, fine granules, granules, Use tablets, coated tablets, capsules, etc.
- liquid preparations such as syrups, injectable preparations, eye drops, etc.
- pH adjusting agents, solubilizers, isotonic agents, etc. and if necessary, solubilizers, stabilizers, buffering agents.
- a suspending agent, antioxidant, etc. and formulate it by a conventional method.
- the solution it can be a lyophilized product.
- the injection can be administered intravenously, subcutaneously or intramuscularly.
- the suspending agent include methyl cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic, tragacanth powder, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, and the like.
- polyoxyethylene hydrogenated castor oil Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, etc .
- suitable stabilizers include sodium sulfite, sodium metasulfite, ether, etc .
- suitable for preservatives examples include methyl paraoxybenzoate, ethyl parabenzoate, sorbic acid, phenol, cresol, closol talesol and the like.
- the pharmaceutical composition described above is useful for the prevention or treatment of various cancer diseases. It is already known that virus therapy using recombinant HSV is effective for all types of solid cancers (see, for example, Non-Patent Document 14 above), and the pharmaceutical composition according to the present invention is used for these cancers. It can be used for everything. Specific diseases include, for example, brain tumor, head and neck cancer, esophageal cancer, stomach cancer, colon cancer, liver cancer, knee cancer, lung cancer, breast cancer, skin cancer, ovarian cancer, prostate cancer, kidney cancer, bladder cancer, melanoma, neuroblast And the like. Especially useful for brain tumors and neuroblastoma.
- the anticancer activity enhancer according to the present invention is characterized in that it is administered in combination with a recombinant herpes simplex virus that selectively replicates cancer cells.
- “administration in combination” is not particularly limited as long as the administration method can provide a synergistic effect by the combination, and the dose, administration method, administration timing, etc. are not particularly limited, and are appropriately selected depending on the therapeutic purpose, disease, and administration target. can do.
- the recombinant HSV and the anticancer effect enhancer may be administered simultaneously, or one of them may be administered first.
- at least one of them may be administered repeatedly or the frequency of administration may be different.
- the anti-cancer effect enhancer is administered repeatedly, and during this period, the thread and the HSV are administered less frequently.
- the administration method of the recombinant HSV is not particularly limited, and the recombinant HSV may be used as it is, or it may be mixed with a pharmaceutically acceptable carrier, stabilizer, emulsifier and the like known per se. You may formulate by the method used.
- the dosage form is not particularly limited and includes capsules, syrups, inhalants, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, lotions and the like, but injection is particularly preferable. It is an agent.
- the present invention also provides a method for preventing or treating cancer, which comprises administering a recombinant herpes simplex virus that selectively replicates cancer cells and an interleukin.
- IL-18 is also synonymous with that used for the above-described anticancer activity enhancer, description thereof is omitted.
- the recombinant HSV is preferably administered by injection into tumor tissue.
- a high cell killing effect can be given to cancer cells in the tissue.
- the administration method is as described above.
- interleukins particularly IL-18
- systemic administration it becomes possible to enhance anti-tumor immunity by simple herpesviruses at sites other than the site of virus administration, and high anticancer activity can be obtained even in metastatic lesions.
- the administration method of interleukin is not particularly limited.
- the cancer therapeutic agent and preventive agent according to the present invention comprises a recombinant HSV that selectively replicates cancer cells, which is used in combination with systemic administration of IL-18, and its ⁇ 34.5 gene. And the ICP 6 gene has been deleted or inactivated, and the gene encoding IL-12 has been inserted into the genomic DNA in an expressible configuration. As described above, such a recombinant HSV can be prepared by inserting a gene encoding IL-12 into the G207 virus genome in an expressible configuration.
- the therapeutic and preventive agents for cancer described above are optimized for the concentration and amount of HSV virus as an active ingredient, assuming that they are administered in combination with IL-18. Yes.
- the therapeutic agent for cancer according to the present invention Since the preventive agent includes recombinant HSV that selectively replicates cancer cells, IL 12 can be secreted only by cancer cells even when administered systemically.
- the recombinant HSV contained in the therapeutic and prophylactic agent for cancer according to the present invention further has its ICP47 gene deleted or inactivated.
- a recombinant HSV can be prepared by inserting the gene encoding IL 12 into the G47 A virus genome described above in a configuration that allows expression, and the ICP47 gene is deleted or inactivated. Because of this, it becomes a safer recombinant HSV.
- Mouse neuroblastoma cell line Neuro2a (5 ⁇ 10 6 cells) was transplanted subcutaneously into AZJ mice and used as a mouse tumor model. Neuro2a is susceptible to HSV infection and is less immunogenic in AZJ mice. Therefore, it is considered that the anti-tumor effect due to the induction of anti-tumor immunity is the model in which the anti-tumor effect is least likely to appear. If this model can show the effectiveness, it can be considered to be effective for other cancers (Todo, T et al .; Cancer Res. 61: 153-161 (2001), Katsanis, E. et al .; Cancer Gene Ther., 2: 39-46 (1995), Katsanis, E. et al .; Cancer Gene Ther ., 3: 75-82 (1996), Heuer, JG, et al .; Hum. Gene Ther., 7: 2059-2068 (1996)).
- mice with 5-6 mm of cancer tissue were divided into groups of 6-7 mice, G47 A (l X 10 6 pfu) was not administered to 2 G47 A administration groups, and 2 G47 A non-administration
- the group (indicated by “mock” in the figure) was injected with phosphate buffered saline (PBS) containing 10% glycerol directly into the cancer tissue twice on days 0 and 3. Administered.
- PBS phosphate buffered saline
- each group of G47 ⁇ administration and non-administration groups was given IL 18 (1 gZ day), PBS was given to the other group, and PBS was administered intraperitoneally every day from day 0 to day 6. It was administered by injection. The tumor tissue was measured, and the volume was calculated from length X width X height (mm).
- Fig. 1 shows the results of repeating the above test twice. In both studies, it was confirmed that the G47 A administration group had a lower rate of increase in cancer volume than the G47 non-administration group. In particular, the combined administration group (country) was stronger than the G47 A alone administration group (oral), and the rate of increase was low.
- mice were extracted from the mouse on the 20th day, and the spleen cells of each mouse were removed. Spleen cells (2 x 10 5 each) were pretreated with mitomycin C in the presence or absence of Neuro2a cells (5 x 10 5 ), 24 hours for IFN-y production test, 48 hours for IL 4 production test Each was cultivated. The number of IFN-y or IL-4 producing cells was determined by ELISPOT assay.
- AZJ mice having a Neuro2a subcutaneous tumor tissue with a diameter of about 4 mm on the left and right abdomen were used.
- G47 A (2 X 10 6 pfu) was added only to the left tumor tissue
- G47 ⁇ In the non-administration group, PBS containing 10% glycerol only in the left tumor tissue was injected twice on day 0 and day 3 (6 mice each).
- IL-18 (1 gZ day) was administered to the IL-18 administration group, and PBS was administered to the IL-18 non-administration group 7 times from day 0 to day 6. It was administered by injection. Measure tumor tissue and length The volume was determined from the X width X height (mm).
- nude mice lacking T lymphocytes were transplanted with Neuro2a tumor cells subcutaneously, and the tumor tissue was about 6 mm in diameter.
- the group was divided into four groups: an 18-administered group, a G47A-administered ZIL-18 non-administered group, a G47A-unadministered ZlL-18-administered group, and a G47A-untreated ZIL-18 non-administered group.
- the dosage and administration method are the same as in Example 1 above.
- G47 ⁇ was injected into the tumor tissue (day 0).
- IL-18 (1 gZ day) was injected into the IL-18 administration group, and the non-administration group Kokoha! 3 ⁇ 43 was injected intraperitoneally seven times from day 0 to day 6.
- the strength of G47 ⁇ was determined after 30 minutes, 2 days, 4 days, 7 days, and 11 days. Measured by Se.
- Anti-CD4 or anti-CD8 antibodies were used to deplete CD4 + T cells or CD8 + T lymphocytes in AZJ mice with Neuro2a subcutaneous tumors, and these immune cells in the combined effect of G47 ⁇ and IL-18 The contribution was verified.
- AZJ mice with 5-6 mm Neuro2a subcutaneous tumor tissue were divided into groups of 6-7 mice, 4 G47 A administration groups were G47 A (2 X 10 6 pfu), 1 control group ( In the figure, “Mock + PBS”), phosphate buffered saline (PBS) containing 10% glycerol was injected directly into the cancer tissue twice on days 0 and 3. Administered.
- anti-CD4 antibody was administered to each of the two groups administered G47 ⁇ -treated ZlL-18 and two groups administered G4 7 ⁇ -treated ZIL-18. (250 ⁇ g) was intraperitoneally administered 1 day before, 2 days, 6 days and 12 days before G4 7 ⁇ administration. As a control, the group that did not receive anti-CD4 antibody was administered the same amount of rat HgG at the same time.
- the CD8-positive T lymphocyte depletion test (right figure) was carried out in the same manner as the CD4-positive T lymphocyte depletion test using anti-CD8 antibody (50 ⁇ g) instead of anti-CD4 antibody.
- the tumor tissue was measured, and the volume was determined from length X width X height (mm).
- G47 A administration group received G47 A (2 X 10 5 pfu), and G47 A non-administration group received 10% glycerol.
- the PBS containing was injected into the tumor tissue.
- IL-18 (1 gZ day) was administered to the IL-18 administration group, PBS was administered to the administration group, and daily injection was carried out intraperitoneally from day 0 to day 6 of G47 A administration. The survival time of the mice was observed.
- IL-12 was administered locally by inserting a gene encoding IL-12 into the recombinant HSV virus genome and administering thread-replaced HSV.
- T-mfIL12 G47 ⁇ virus DNA in which a gene encoding IL-12 was inserted in an expressible configuration was prepared. did.
- box on the line indicates the U sequence unique to herpesvirus DNA and
- Both 2 and ⁇ 34.5 f pi 1.
- This has a deletion of Okb, a position of ICP47, a deletion of 312 bp, and 3 of the ICP6 gene. It has 8941 ⁇ deletion between & 1 and 1101 sites.
- I c The mouse IL-12 gene (indicated by “transgene” in the figure) and the LacZ gene were inserted into the P6 deletion site.
- a thick arrow is a transcription region.
- N is NcoI
- Bs is BstEII
- St Stul
- X XhoI
- B is BamHI
- Sc Scal
- G is BglII
- EN EcoNI
- Nr is a restriction site by Nrul.
- AZJ mice having a Neuro2a subcutaneous tumor tissue with a diameter of about 5 mm in the left and right abdomen were used, and T-mfIL12 (l X 10 6 pfu) (10 In the non-administered group, only PBS containing 10% glycerol was injected twice on day 0 and day 3 respectively (in each PBS). 6 each).
- IL-18 (1 gZ day) was injected into the IL-18 administration group, and PBS was injected into the abdominal cavity 7 times from day 0 to day 6 for the IL non-administration group. Administered. The tumor tissue was measured, and the volume was determined from length X width X height (mm).
- the tumor growth was significantly suppressed by T-mfIL12 alone ( ⁇ ) compared to the non-virus-treated group ( ⁇ and ⁇ ), but combined use of T-mfIL12 and IL-18 ( ⁇ ) showed a significantly stronger antitumor effect.
- the T-mfIL12 alone administration group showed only mild suppression of tumor growth compared to the virus non-administration group.
- the antitumor effect was markedly enhanced, showing a significant difference from the T-mfIL12 single administration group.
- FIG. 1 shows the results of testing the effect of combined administration of G47 ⁇ and IL-18 on mice with subcutaneous Neuro2a tumors.
- FIG. 2 shows the results of a test to verify the induction of splenocytes in response to tumor cell stimulation by the combined administration of G47 ⁇ and IL-18.
- FIG. 3 shows the results of testing the anticancer effect of G47 ⁇ and IL-18 in combination with a remote tumor tissue not administered with G47 ⁇ .
- FIG. 4 shows the results of testing the effect of combined administration of G47 ⁇ and IL-18 in nude mice.
- FIG. 5 shows the results of testing the effect of IL-18 administration on virus replication of G47 ⁇ in cancer tissues.
- FIG. 6 shows the results of testing the effect of combined administration of G47 ⁇ and IL-18 under the wilt of CD4 + or CD8 + T lymphocytes.
- FIG. 7 shows the results of testing the effect of combined administration of G47 ⁇ and IL-18 on brain tumors.
- FIG. 8 shows the structure of G47 ⁇ virus DNA (T-mfIL12) into which a gene encoding IL-12 has been inserted in an expressible configuration.
- FIG. 9 Mice with subcutaneous Neuro2a tumor on both sides were administered virus administration when G47 ⁇ expressing IL-12 (local administration to left tumor) and IL-18 (systemic administration) were administered together Results of testing antitumor effects on tumor (left side) and distant tumor (right side) are shown.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2563103A CA2563103C (en) | 2004-03-31 | 2005-03-31 | Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer |
US10/594,964 US7655459B2 (en) | 2004-03-31 | 2005-03-31 | Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer |
JP2006511831A JP5522884B2 (ja) | 2004-03-31 | 2005-03-31 | ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 |
EP05727510.9A EP1736169B1 (en) | 2004-03-31 | 2005-03-31 | Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment |
AU2005228788A AU2005228788B2 (en) | 2004-03-31 | 2005-03-31 | Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment |
ES05727510.9T ES2463442T3 (es) | 2004-03-31 | 2005-03-31 | Potenciador de la actividad anticancerosa en terapia viral y método de prevención o de tratamiento del cáncer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-105487 | 2004-03-31 | ||
JP2004105487 | 2004-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094867A1 true WO2005094867A1 (ja) | 2005-10-13 |
Family
ID=35063526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006398 WO2005094867A1 (ja) | 2004-03-31 | 2005-03-31 | ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7655459B2 (ja) |
EP (1) | EP1736169B1 (ja) |
JP (1) | JP5522884B2 (ja) |
AU (1) | AU2005228788B2 (ja) |
CA (1) | CA2563103C (ja) |
ES (1) | ES2463442T3 (ja) |
WO (1) | WO2005094867A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015508156A (ja) * | 2012-01-25 | 2015-03-16 | ディーエヌエートリックス インコーポレイテッド | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008033499A2 (en) * | 2006-09-14 | 2008-03-20 | The Trustees Of The University Of Pennsylvania | Modulation of regulatory t cells by human il-18 |
WO2009148488A2 (en) * | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513508A (ja) * | 1997-08-12 | 2001-09-04 | ジョージタウン ユニバーシティー | 腫瘍治療を目的とするヘルペスベクターの使用 |
WO2002076216A1 (en) | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE371031T1 (de) * | 1999-06-08 | 2007-09-15 | Uab Research Foundation | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs |
CN1250732C (zh) * | 2000-01-21 | 2006-04-12 | 拜奥维克斯有限公司 | 病毒株 |
-
2005
- 2005-03-31 WO PCT/JP2005/006398 patent/WO2005094867A1/ja active Application Filing
- 2005-03-31 CA CA2563103A patent/CA2563103C/en active Active
- 2005-03-31 US US10/594,964 patent/US7655459B2/en active Active
- 2005-03-31 EP EP05727510.9A patent/EP1736169B1/en active Active
- 2005-03-31 JP JP2006511831A patent/JP5522884B2/ja active Active
- 2005-03-31 ES ES05727510.9T patent/ES2463442T3/es active Active
- 2005-03-31 AU AU2005228788A patent/AU2005228788B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513508A (ja) * | 1997-08-12 | 2001-09-04 | ジョージタウン ユニバーシティー | 腫瘍治療を目的とするヘルペスベクターの使用 |
WO2002076216A1 (en) | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
US20020187163A1 (en) | 2001-03-27 | 2002-12-12 | Paul Johnson | Viral vectors and their use in therapeutic methods |
Non-Patent Citations (30)
Title |
---|
"Seikagaku Jiten (3rd edition)", 1998, article KABUSHIKI: "Kaisha Tokyo Kagaku Dojin", pages: 154 - 157, XP002992635 * |
CHAHLAVI, A. ET AL., GENE THER., vol. 6, 1999, pages 1751 - 1758 |
CHAHLAVI, A. ET AL., NEOPLASIA, vol. 1, 1999, pages 162 - 169 |
CORDOBA-RODRIGUEZ, R., EXPERT OPIN. BIOL. THER., vol. 3, no. 5, August 2003 (2003-08-01), pages 715 - 23 |
FUJIOKA ET AL., J. OF VIROLOGY, March 1999 (1999-03-01), pages 2401 - 2409 |
HARA I ET AL., CANCER GENE THERAPY, vol. 7, 2000, pages 83 - 90 |
HEUER, J.G. ET AL., HUM. GENE THER., vol. 7, 1996, pages 2059 - 2068 |
HUNTER, W.D. ET AL., J. VIROL., vol. 73, 1999, pages 6319 - 6326 |
JORGENSEN, T.J. ET AL., NEOPLASIA, vol. 3, 2001, pages 451 - 456 |
KATSANIS, E. ET AL., CANCER GENE THER., vol. 2, 1995, pages 39 - 46 |
KATSANIS, E. ET AL., CANCER GENE THER., vol. 3, 1996, pages 75 - 82 |
MALMGAARD ET AL., J. OF GENERAL VIROLOGY, vol. 84, 2003, pages 2497 - 2500 |
MARKERT, J.M. ET AL., GENE THER., vol. 7, 2000, pages 867 - 874 |
MARTUZA, R. L. ET AL., SCIENCE, vol. 252, 1991, pages 854 - 6 |
MARTUZA, R.L. ET AL., SCIENCE, vol. 252, 1991, pages 854 - 6 |
NAKAMURA, S. ET AL., GLIA, vol. 28, 1999, pages 53 - 65 |
NAKANO, K. ET AL., MOL. THER., vol. 3, 2001, pages 431 - 437 |
See also references of EP1736169A4 * |
TODA M ET AL., J. IMMUNOL., vol. 160, pages 4457 - 4464 |
TODA M. ET AL., HUM. GENE THER., vol. 10, 1999, pages 385 - 393 |
TODO T. ET AL: "Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing", PROC.NATL.ACAD.SCI. USA, vol. 98, no. 11, 2001, pages 6396 - 6401, XP002989849 * |
TODO, T. ET AL., CANCER GENE THER., vol. 7, 2000, pages 939 - 946 |
TODO, T. ET AL., CANCER RES., vol. 61, 2001, pages 153 - 161 |
TODO, T. ET AL., HUM. GENE THER., vol. 10, 1999, pages 2741 - 2755 |
TODO, T. ET AL., HUM. GENE THER., vol. 10, 1999, pages 2869 - 2878 |
TODO, T. ET AL., MOL. THER., vol. 2, 2000, pages 588 - 595 |
TODO, T. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 6396 - 6401 |
TODO, T. ET AL.: "NEOPLASIA", 2001, ACADEMIC PRESS, pages: 45 - 75 |
VARGHESE S. ET AL: "Oncolytic herpes simplex virus vectors for cancer virotherapy", CANCER GENE THERAPY, vol. 9, no. 12, 2002, pages 967 - 978, XP002313119 * |
VARGHESE, S. ET AL., HUM. GENE THER., vol. 12, 2001, pages 999 - 1010 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015508156A (ja) * | 2012-01-25 | 2015-03-16 | ディーエヌエートリックス インコーポレイテッド | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
US10238698B2 (en) | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
JP2019066482A (ja) * | 2012-01-25 | 2019-04-25 | ディーエヌエートリックス インコーポレイテッド | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
US11065285B2 (en) | 2012-01-25 | 2021-07-20 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
Also Published As
Publication number | Publication date |
---|---|
US7655459B2 (en) | 2010-02-02 |
AU2005228788B2 (en) | 2010-12-02 |
CA2563103A1 (en) | 2005-10-13 |
JPWO2005094867A1 (ja) | 2008-02-14 |
US20070154451A1 (en) | 2007-07-05 |
EP1736169A1 (en) | 2006-12-27 |
EP1736169A4 (en) | 2009-08-12 |
CA2563103C (en) | 2015-02-17 |
AU2005228788A1 (en) | 2005-10-13 |
JP5522884B2 (ja) | 2014-06-18 |
EP1736169B1 (en) | 2014-03-26 |
ES2463442T3 (es) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wong et al. | Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma | |
ES2366608T3 (es) | Vectores víricos y su uso en métodos terapéuticos. | |
CN1829523B (zh) | 病毒载体 | |
Manservigi et al. | HSV recombinant vectors for gene therapy | |
ES2276470T3 (es) | Utilizacion de vectores de herpes para la terapia tumoral. | |
Watanabe et al. | Oncolytic virotherapy by HSV | |
Todo et al. | Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replicationcompetent herpes simplex virus tumor therapy | |
WO2011119925A2 (en) | Synthetic herpes simplex viruses for treatment of cancers | |
Scanlan et al. | Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers | |
Alkayyal et al. | Interleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy | |
Liu et al. | Advance in herpes simplex viruses for cancer therapy | |
US20230026342A1 (en) | New generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use | |
ES2233349T3 (es) | Reordenacion por promotores especificos para una celula y/o especificos para un tumor de la expresion del gen gamma 34,5 herpetico. | |
JP5522884B2 (ja) | ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 | |
JPWO2005103237A1 (ja) | 組換え単純ヘルペスウイルスの作製方法 | |
Argnani et al. | Replication-competent herpes simplex vectors: design and applications | |
US20220002680A1 (en) | Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use | |
Yeung et al. | Replicating herpes simplex virus vectors for cancer gene therapy | |
Li et al. | Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine | |
Hunter et al. | Brain tumor therapy using genetically engineered replication-competent virus | |
Todo et al. | Oncolytic herpes simplex virus (G207) therapy: from basic to clinical | |
WO2022048574A1 (zh) | 一种编码Kras基因突变体的核酸分子 | |
Ha et al. | OPEN ACCESS EDITED BY loana Berindan Neagoe, Iuliu Hațieganu University of Medicine and Pharmacy, Romania | |
WO2021024897A1 (ja) | 悪性腫瘍を治療するための併用薬、悪性腫瘍を治療するための医薬組成物、および、悪性腫瘍治療用医薬組成物 | |
Fukuhara et al. | New generation of oncolytic herpes virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511831 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005228788 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2563103 Country of ref document: CA Ref document number: 10594964 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727510 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005228788 Country of ref document: AU Date of ref document: 20050331 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005228788 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727510 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10594964 Country of ref document: US |